PL420626A1 - New derivatives of carbamates and their application - Google Patents

New derivatives of carbamates and their application

Info

Publication number
PL420626A1
PL420626A1 PL420626A PL42062617A PL420626A1 PL 420626 A1 PL420626 A1 PL 420626A1 PL 420626 A PL420626 A PL 420626A PL 42062617 A PL42062617 A PL 42062617A PL 420626 A1 PL420626 A1 PL 420626A1
Authority
PL
Poland
Prior art keywords
application
methyl
carbamates
new derivatives
ethyl
Prior art date
Application number
PL420626A
Other languages
Polish (pl)
Other versions
PL232830B1 (en
Inventor
Dariusz Kozakiewicz
Jarosław Polański
Josef Jampilek
Ales Imramowsky
Sarka Stepankova
Original Assignee
Uniwersytet Śląski W Katowicach
Dk Chem Organic Synthesis Ltd Spółka Komandytowa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Śląski W Katowicach, Dk Chem Organic Synthesis Ltd Spółka Komandytowa filed Critical Uniwersytet Śląski W Katowicach
Priority to PL420626A priority Critical patent/PL232830B1/en
Publication of PL420626A1 publication Critical patent/PL420626A1/en
Publication of PL232830B1 publication Critical patent/PL232830B1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest nowa pochodna karbaminianów, która charakteryzuje się tym, że ma strukturę chemiczną o wzorze ogólnym 1, gdzie R1 stanowi grupę metylową, etylową lub propylową, R2 - grupę metylową lub etylową, R3 - grupę metylową, fenylową lub benzylową. Zgłoszenie obejmuje też zastosowanie przedmiotowych związków do wytwarzania substancji czynnych przeznaczonych do leczenia choroby Alzheimera.The subject of the application is a new carbamate derivative, which is characterized in that it has a chemical structure of general formula 1, where R1 is a methyl, ethyl or propyl group, R2 is a methyl or ethyl group, R3 is a methyl, phenyl or benzyl group. The application also includes the use of the subject compounds for the production of active substances intended for the treatment of Alzheimer's disease.

PL420626A 2017-02-23 2017-02-23 New derivatives of carbamates and their application PL232830B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL420626A PL232830B1 (en) 2017-02-23 2017-02-23 New derivatives of carbamates and their application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL420626A PL232830B1 (en) 2017-02-23 2017-02-23 New derivatives of carbamates and their application

Publications (2)

Publication Number Publication Date
PL420626A1 true PL420626A1 (en) 2018-08-27
PL232830B1 PL232830B1 (en) 2019-07-31

Family

ID=63229461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL420626A PL232830B1 (en) 2017-02-23 2017-02-23 New derivatives of carbamates and their application

Country Status (1)

Country Link
PL (1) PL232830B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137453A1 (en) * 2022-01-14 2023-07-20 Terran Biosciences Inc. Prodrugs of 3,4-methylenedioxy-n-methcathinone and uses thereof
WO2024039599A1 (en) * 2022-08-17 2024-02-22 Transcend Therapeutics, Inc. Phenethylamines and cathinones precursors

Also Published As

Publication number Publication date
PL232830B1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CY1124257T1 (en) N-[4-PHTOPO-5-[[(2S,4S)-2-METHYLO-4-[(5-METHYLO-1,2,4-OXADIAZOL-3-YLO)METHOXY]-l-PIPERIDYL]METHYL] THIAZOL-2-YL]ACETAMIDE AS AN OGA INHIBITOR
CO2020000145A2 (en) Carboxamides as sodium channel modulators
PH12016501813A1 (en) 1,3-benzodioxole derivative
CY1119361T1 (en) 3,4-Dihydroisoquinoline-2 (1H) -Material Compounds
UY37205A (en) BROMODOMINIUM INHIBITORS
MX2015008957A (en) Fluoro-[1,3]oxazines as bace1 inhibitors.
MX2017006447A (en) Antifungal agents.
CY1117583T1 (en) SOLID FORMS INCLUDING N- (5-Tert-butyl-isoxazol-3-yl) -n΄- {4- [7- (2-morpholin-4-yl-ethoxy) imidazo [2,1] 3] BENZOTHEIZOL-2-YL] FINAL} URINARY, COMPOSITIONS OUTSIDE, AND USES THEREOF
AR100818A1 (en) N- (CYANOMETIL) -4- (2- (4-MORFOLINOFENILAMINO) PIRIMIDIN-4-IL) BENZAMIDA
BR112017004673A2 (en) 2- (4- (4-Ethoxy-6-oxo-1,6-dihydropyridin-3-yl) -2-fluorophenyl) -n- (5- (1,1,1-trifluoro-2-methylpropan) crystalline forms -2-yl) isoxazol-3-yl) acetamide
UA113538C2 (en) FLUOROMETHYL-5,6-DIHYDRO-4H- $ 1,3] OXAZINES
EA201790627A1 (en) STEMULATORS RHC
EA201591541A1 (en) BETA SECRETASE INHIBITORS 1 (BACE 1)
CO7131369A2 (en) 5-amino [1,4] thiazines as bace1 inhibitors
CL2018003431A1 (en) Treatment of parkinson's disease.
MX2019011774A (en) Substituted n-(-1,3,4-oxadiazole-2-yl)aryl carboxamides and the use thereof as herbicides.
PL420626A1 (en) New derivatives of carbamates and their application
MX2019002104A (en) 3-pyridyloxyphenyldihydrouracil compound and use thereof.
EA201990766A1 (en) INDOSOLIC COMPOUNDS FOR USE IN DAMAGE OF THE TENDON AND / OR Ligaments
BR112018074162A2 (en) pharmaceutical compositions suitable for oral administration and parenteral administration, methods for preventing or treating fungal infection in a human or animal individual and for producing a pharmaceutical composition, and use of a pharmaceutical composition.
PH12017501668A1 (en) Bace1 inhibitors
PL420629A1 (en) New derivatives of carbamates and their application
CL2016003230A1 (en) Compounds, pharmaceutical composition and its use in the treatment of neurodegenerative diseases
BR112018013356A2 (en) hydrochloride salt, crystalline forms of a hydrochloride salt and pharmaceutical composition
AR112040A1 (en) SALT OF N- (2,6-DIETHYLPHENYL) -8 - ({4- [4- (DIMETHYLAMINO) PIPERIDIN-1-IL] -2-METOXIFENIL} AMINO) -1-METIL-4,5-DIHIDRO-1H- PIRAZOLO [4,3-H] QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND THE FORMULATIONS CONTAINING IT